Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Esophageal Neoplasms 25Rectal Neoplasms 23Glioblastoma 23Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Breast Neoplasms 17Pancreatic Neoplasms 16Lung Neoplasms 16Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 14Neoplasms 12Oropharyngeal Neoplasms 11Neoplasm Metastasis 10Esophageal Squamous Cell Carcinoma 9Adenocarcinoma Of Esophagus 8Uterine Cervical Neoplasms 7Glioma 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Gliosarcoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Melanoma 5Laryngeal Neoplasms 5Colorectal Neoplasms 5Xerostomia 4Sarcoma 4Mouth Neoplasms 4

Interventions

Amifostine 10Cisplatin 8Radiotherapy 7Etoposide 6Cyclophosphamide 4Carboplatin 4Paclitaxel 3pegfilgrastim 2camrelizumab 2apatinib 2Mitoxantrone 2Filgrastim 2Drug Therapy 2Cytarabine 2sodium thiosulfate 1sargramostim 1pazopanib 1icotinib 1glucarpidase 1etoposide phosphate 1denileukin diftitox 1Vitamin E 1Triptorelin Pamoate 1Tocopherols 1Thiotepa 1Tegafur 1Taxes 1Surgical Procedures, Operative 1Silymarin 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Drug-Related Side Effects and Adverse Reactions × Radiation × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡